Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

APOA5 anticorps (N-Term)

APOA5 Reactivité: Humain WB, IHC (p) Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN543847
  • Antigène Voir toutes APOA5 Anticorps
    APOA5 (Apolipoprotein A-V (APOA5))
    Épitope
    • 9
    • 7
    • 5
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    N-Term
    Reactivité
    • 52
    • 10
    • 7
    • 2
    • 1
    • 1
    Humain
    Hôte
    • 42
    • 18
    • 1
    Lapin
    Clonalité
    • 44
    • 18
    Polyclonal
    Conjugué
    • 39
    • 7
    • 5
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp APOA5 est non-conjugé
    Application
    • 42
    • 23
    • 23
    • 12
    • 6
    • 5
    • 4
    • 4
    • 4
    • 4
    • 2
    • 1
    Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
    Fonction
    Rabbit polyclonal antibody raised against synthetic peptide of APOA5.
     Réactivité croisée
    Humain
    Immunogène
    A synthetic peptide (conjugated with KLH) corresponding to N-terminus of human APOA5.
    Top Product
    Discover our top product APOA5 Anticorps primaire
  • Indications d'application
    Western Blot (1:1000)
    Immunohistochemistry (1:10-50)
    The optimal working dilution should be determined by the end user.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    In PBS (0.09 % sodium azide)
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C,-20 °C
    Stockage commentaire
    Store at 4°C. For long term storage store at -20°C.
    Aliquot to avoid repeated freezing and thawing.
  • Hubacek, Wang, Skodová, Adámková, Vráblík, Horínek, Stulc, Ceska, Talmud: "APOA5 Ala315>Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels." dans: Clinical chemistry and laboratory medicine : CCLM / FESCC, Vol. 46, Issue 6, pp. 773-7, (2008) (PubMed).

    Dorfmeister, Zeng, Dichlberger, Nilsson, Schaap, Hubacek, Merkel, Cooper, Lookene, Putt, Whittall, Lee, Lins, Delsaux, Nierman, Kuivenhoven, Kastelein, Vrablik, Olivecrona, Schneider, Heeren et al.: "Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding. ..." dans: Arteriosclerosis, thrombosis, and vascular biology, Vol. 28, Issue 10, pp. 1866-71, (2008) (PubMed).

    Luo, Kranzler, Zuo, Wang, Blumberg, Gelernter: "CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study." dans: Human molecular genetics, Vol. 14, Issue 16, pp. 2421-34, (2005) (PubMed).

  • Antigène
    APOA5 (Apolipoprotein A-V (APOA5))
    Autre désignation
    Apolipoprotein A V (ApoA V) (APOA5 Produits)
    Synonymes
    anticorps APOAV, anticorps RAP3, anticorps 1300007O05Rik, anticorps Apoav, anticorps apo-AV, anticorps apoA-V, anticorps APOA5, anticorps MGC140487, anticorps rap3, anticorps apoav, anticorps apoa-v, anticorps apolipoprotein A5, anticorps apolipoprotein A-V, anticorps apolipoprotein A5 L homeolog, anticorps APOA5, anticorps Apoa5, anticorps apoa5.L, anticorps apoa5
    ID gène
    116519
    Pathways
    Regulation of Lipid Metabolism by PPARalpha, Lipid Metabolism
Vous êtes ici:
Support technique